Targeting the intestinal lymphatic system: a versatile path for enhanced oral bioavailability of drugs

Renuka Suresh Managuli, Sushil Yadaorao Raut, Meka Sreenivasa Reddy, Srinivas Mutalik

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Introduction: The major challenge of first pass metabolism in oral drug delivery can be surmounted by directing delivery toward intestinal lymphatic system (ILS). ILS circumvents the liver and transports drug directly into systemic circulation via thoracic duct. Lipid and polymeric nanoparticles are transported into ILS through lacteal and Peyer’s patches. Moreover, surface modification of nanoparticles with ligand which is specific for Peyer’s patches enhances the uptake of drugs into ILS. Bioavailability enhancement by lymphatic uptake is an advantageous approach adopted by scientists today. Therefore, it is important to understand clear insight of ILS in targeted drug delivery and challenges involved in it. Areas covered: Current review includes an overview of ILS, factors governing lymphatic transport of nanoparticles and absorption mechanism of lipid and polymeric nanoparticles into ILS. Various ligands used to target Peyer’s patch and their conjugation strategies to nanoparticles are explained in detail. In vitro and in vivo models used to assess intestinal lymphatic transport of molecules are discussed further. Expert opinion: Although ILS offers a versatile pathway for nanotechnology based targeted drug delivery, extensive investigations on validation of the lymphatic transport models and on the strategies for gastric protection of targeted nanocarriers have to be perceived in for excellent performance of ILS in oral drug delivery.

Original languageEnglish
Pages (from-to)787-804
Number of pages18
JournalExpert Opinion on Drug Delivery
Volume15
Issue number8
DOIs
Publication statusPublished - 03-08-2018

Fingerprint

Lymphatic System
Biological Availability
Nanoparticles
Pharmaceutical Preparations
Peyer's Patches
Ligands
Lipids
Thoracic Duct
Nanotechnology
Expert Testimony
Stomach
Milk

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science

Cite this

@article{940be15525574d859fd63e23aa788d67,
title = "Targeting the intestinal lymphatic system: a versatile path for enhanced oral bioavailability of drugs",
abstract = "Introduction: The major challenge of first pass metabolism in oral drug delivery can be surmounted by directing delivery toward intestinal lymphatic system (ILS). ILS circumvents the liver and transports drug directly into systemic circulation via thoracic duct. Lipid and polymeric nanoparticles are transported into ILS through lacteal and Peyer’s patches. Moreover, surface modification of nanoparticles with ligand which is specific for Peyer’s patches enhances the uptake of drugs into ILS. Bioavailability enhancement by lymphatic uptake is an advantageous approach adopted by scientists today. Therefore, it is important to understand clear insight of ILS in targeted drug delivery and challenges involved in it. Areas covered: Current review includes an overview of ILS, factors governing lymphatic transport of nanoparticles and absorption mechanism of lipid and polymeric nanoparticles into ILS. Various ligands used to target Peyer’s patch and their conjugation strategies to nanoparticles are explained in detail. In vitro and in vivo models used to assess intestinal lymphatic transport of molecules are discussed further. Expert opinion: Although ILS offers a versatile pathway for nanotechnology based targeted drug delivery, extensive investigations on validation of the lymphatic transport models and on the strategies for gastric protection of targeted nanocarriers have to be perceived in for excellent performance of ILS in oral drug delivery.",
author = "Managuli, {Renuka Suresh} and Raut, {Sushil Yadaorao} and Reddy, {Meka Sreenivasa} and Srinivas Mutalik",
year = "2018",
month = "8",
day = "3",
doi = "10.1080/17425247.2018.1503249",
language = "English",
volume = "15",
pages = "787--804",
journal = "Expert Opinion on Drug Delivery",
issn = "1742-5247",
publisher = "Informa Healthcare",
number = "8",

}

Targeting the intestinal lymphatic system : a versatile path for enhanced oral bioavailability of drugs. / Managuli, Renuka Suresh; Raut, Sushil Yadaorao; Reddy, Meka Sreenivasa; Mutalik, Srinivas.

In: Expert Opinion on Drug Delivery, Vol. 15, No. 8, 03.08.2018, p. 787-804.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Targeting the intestinal lymphatic system

T2 - a versatile path for enhanced oral bioavailability of drugs

AU - Managuli, Renuka Suresh

AU - Raut, Sushil Yadaorao

AU - Reddy, Meka Sreenivasa

AU - Mutalik, Srinivas

PY - 2018/8/3

Y1 - 2018/8/3

N2 - Introduction: The major challenge of first pass metabolism in oral drug delivery can be surmounted by directing delivery toward intestinal lymphatic system (ILS). ILS circumvents the liver and transports drug directly into systemic circulation via thoracic duct. Lipid and polymeric nanoparticles are transported into ILS through lacteal and Peyer’s patches. Moreover, surface modification of nanoparticles with ligand which is specific for Peyer’s patches enhances the uptake of drugs into ILS. Bioavailability enhancement by lymphatic uptake is an advantageous approach adopted by scientists today. Therefore, it is important to understand clear insight of ILS in targeted drug delivery and challenges involved in it. Areas covered: Current review includes an overview of ILS, factors governing lymphatic transport of nanoparticles and absorption mechanism of lipid and polymeric nanoparticles into ILS. Various ligands used to target Peyer’s patch and their conjugation strategies to nanoparticles are explained in detail. In vitro and in vivo models used to assess intestinal lymphatic transport of molecules are discussed further. Expert opinion: Although ILS offers a versatile pathway for nanotechnology based targeted drug delivery, extensive investigations on validation of the lymphatic transport models and on the strategies for gastric protection of targeted nanocarriers have to be perceived in for excellent performance of ILS in oral drug delivery.

AB - Introduction: The major challenge of first pass metabolism in oral drug delivery can be surmounted by directing delivery toward intestinal lymphatic system (ILS). ILS circumvents the liver and transports drug directly into systemic circulation via thoracic duct. Lipid and polymeric nanoparticles are transported into ILS through lacteal and Peyer’s patches. Moreover, surface modification of nanoparticles with ligand which is specific for Peyer’s patches enhances the uptake of drugs into ILS. Bioavailability enhancement by lymphatic uptake is an advantageous approach adopted by scientists today. Therefore, it is important to understand clear insight of ILS in targeted drug delivery and challenges involved in it. Areas covered: Current review includes an overview of ILS, factors governing lymphatic transport of nanoparticles and absorption mechanism of lipid and polymeric nanoparticles into ILS. Various ligands used to target Peyer’s patch and their conjugation strategies to nanoparticles are explained in detail. In vitro and in vivo models used to assess intestinal lymphatic transport of molecules are discussed further. Expert opinion: Although ILS offers a versatile pathway for nanotechnology based targeted drug delivery, extensive investigations on validation of the lymphatic transport models and on the strategies for gastric protection of targeted nanocarriers have to be perceived in for excellent performance of ILS in oral drug delivery.

UR - http://www.scopus.com/inward/record.url?scp=85052243056&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052243056&partnerID=8YFLogxK

U2 - 10.1080/17425247.2018.1503249

DO - 10.1080/17425247.2018.1503249

M3 - Review article

AN - SCOPUS:85052243056

VL - 15

SP - 787

EP - 804

JO - Expert Opinion on Drug Delivery

JF - Expert Opinion on Drug Delivery

SN - 1742-5247

IS - 8

ER -